Skip to main
SKIN

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 0%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

The Beauty Health Company has demonstrated a strong performance with a fourth-quarter revenue of $96.8 million, exceeding previous estimates and indicating positive momentum in the market. A notable 20% quarter-over-quarter growth in average selling price (ASP) of total systems to $28.8K is attributed to an increased proportion of direct sales, enhancing profitability. Despite being back-end weighted, the encouraging EBITDA guidance and revenue upside driven by consumables signify a robust outlook for the company's future financial performance.

Bears say

The Beauty Health Company's performance has raised concerns, particularly with new placements of core delivery systems declining over 30% year-over-year and quarter-over-quarter, falling significantly short of prior estimates. This slowdown in new system placements threatens future consumables sales, crucial for achieving the company's profitability goals in 2024, especially given that management has provided lower-than-expected first-quarter sales and adjusted EBITDA guidance. Additionally, significant risks including brand integrity, macroeconomic conditions impacting consumer spending, and challenges in the Syndeo upgrade cycle further complicate the company's outlook and undermine its growth potential.

SKIN has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Hold based on their latest research and market trends.

According to 4 analysts, SKIN has a Hold consensus rating as of Mar 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.02, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.02, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.